Efficacy and safety of pegylated-interferon α-2a in myelofibrosis: a study by the FIM and GEM French cooperative groups

Experience with pegylated interferon  -2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients

(2012) K. Gowin et al.   HAEMATOLOGICA

Improving Survival Trends in Primary Myelofibrosis: An International Study

(2012) Francisco Cervantes et al.   JOURNAL OF CLINICAL ONCOLOGY

Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs

(2012) Robyn M. Emanuel et al.   JOURNAL OF CLINICAL ONCOLOGY

A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

(2012) Srdan Verstovsek et al.   NEW ENGLAND JOURNAL OF MEDICINE

JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis

(2012) Claire Harrison et al.   NEW ENGLAND JOURNAL OF MEDICINE

Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management

(2011) Ayalew Tefferi   AMERICAN JOURNAL OF HEMATOLOGY

Comparison of thalidomide and lenalidomide as therapy for myelofibrosis

(2011) E. Jabbour et al.   BLOOD

Indications for and current results with allogeneic hematopoietic cell transplantation in patients with myelofibrosis

(2011) H. J. Deeg et al.   BLOOD

How I treat myelofibrosis

(2011) A. Tefferi   BLOOD

Recombinant interferon-  may retard progression of early primary myelofibrosis: a preliminary report

(2011) R. T. Silver et al.   BLOOD

The renaissance of interferon therapy for the treatment of myeloid malignancies

(2011) J.-J. Kiladjian et al.   BLOOD

Therapeutic approaches in myelofibrosis

(2011) Giovanni Barosi et al.   EXPERT OPINION ON PHARMACOTHERAPY

Interferon Alfa in the Treatment of Philadelphia-Negative Chronic Myeloproliferative Neoplasms

(2011) Hans Carl Hasselbalch et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis

(2011) Animesh Pardanani et al.   JOURNAL OF CLINICAL ONCOLOGY

Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet

(2011) Tiziano Barbui et al.   JOURNAL OF CLINICAL ONCOLOGY

Transplantation for myelofibrosis: Time for a randomized trial

(2011) Ruben A. Mesa   LEUKEMIA RESEARCH

Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903

(2010) R. A. Mesa et al.   BLOOD

Retrospective study of allogeneic haematopoietic stem-cell transplantation for myelofibrosis

(2010) S Lissandre et al.   BONE MARROW TRANSPLANTATION

Alpha interferon in the treatment of symptomatic myelofibrosis with myeloid metaplasia

(2010) L. Parmeggiani et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Classification and diagnosis of myeloproliferative neoplasms according to the 2008 World Health Organization criteria

(2010) Martha Wadleigh et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status

(2010) Naseema Gangat et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase-2 trial of low-dose pomalidomide in myelofibrosis

(2010) K H Begna et al.   LEUKEMIA

What are RBC-transfusion-dependence and -independence?

(2010) R.P. Gale et al.   LEUKEMIA RESEARCH

Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis

(2010) Srdan Verstovsek et al.   NEW ENGLAND JOURNAL OF MEDICINE

A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)

(2009) F. Passamonti et al.   BLOOD

PEG-IFN-α-2a therapy in patients with myelofibrosis

(2009) Jean-Christophe Ianotto et al.   BRITISH JOURNAL OF HAEMATOLOGY

Pegylated Interferon Alfa-2a Yields High Rates of Hematologic and Molecular Response in Patients With Advanced Essential Thrombocythemia and Polycythemia Vera

(2009) Alfonso Quintás-Cardama et al.   JOURNAL OF CLINICAL ONCOLOGY

Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera

(2008) J.-J. Kiladjian et al.   BLOOD

New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment

(2008) F. Cervantes et al.   BLOOD